Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels can deliver small hydrophobic molecular inhibitors and water-soluble protein cytokines in a sustained way to the tumor microenvironment to enhance tumor immunotherapy [55]. The gene discussed is TGFB1; the disease is neoplasm.